The FDA on September 20, 2024, approved SARCLISA® with Bortezomib, Lenalidomide, and Dexamethasone for adults with newly diagnosed Multiple Myeloma who are not eligible for Autologous Stem Cell Transplant (ASCT). SARCLISA® is a product of Sanofi-Aventis U.S., LLC.
Bottom Ad
Advertisement
Subscribe
